Dr. Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, a biopharmaceutical company developing treatments for life-threatening food allergies, discusses the company’s lead candidate AR101, CODIT (Characterized Oral Desensitization Immunotherapy) approach to treating food allergies and the broader food allergy landscape.
With 23 years of clinical practice as a board-certified allergist and immunologist, Stephen A. Tilles, MD, is Senior Director of Medical Affairs at Aimmune Therapeutics. In addition to this role, he currently serves as Clinical Professor of Medicine at the University of Washington and is a Fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma, and Was Immunology (ACAAI).
His previous roles include President of the ACAAI, Assistant Professor of Medicine and Pediatrics and Director of the Allergy and Asthma Clinic at Oregon Health Sciences University (OHSU), and serving on both the Joint Task Force for Practice Parameters and the American Board of Allergy and Immunology.
Dr. Tilles has been a principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 trials evaluating treatments for food allergy. He has authored more than 100 papers in peer-reviewed publications.
Dr. Tilles joined the Medical Affairs team at Aimmune because he is passionate about pioneering new treatments and advancing the field of immunotherapy, understanding the significance of an evidence-based treatment option is paramount to changing the lives of those who live with food allergies.
He received his MD from the University of California San Diego School of Medicine, completed residency training at OHSU, and completed a fellowship in allergy and immunology at the National Jewish Center for Immunology and Respiratory Medicine. He is board certified by the American Board of Allergy and Immunology.